Celcuity Inc. (CELC) shareholders
CELCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$64.17−0.15 (-0.23%)
Close on Nov 12, 2026Market cap $3.14BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
57M of 49M shares
Institutional holders
274
61 new, 60 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $327.56M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (18.90%), Baker Bros. Advisors (GP) LLC (18.90%) and 1 more | 7,745,692 | 18.90% | 13D (active) | Aug 1, 2025 |
| Baker Bros. Advisors (GP) LLC Joint filing with Baker Bros. Advisors LP (9.99%), Julian C. Baker (9.99%) and 1 more | 4,877,963 | 9.99% | 13D (active) amendment | Jul 14, 2026 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (9.99%), Julian C. Baker (9.99%) and 1 more | 4,877,963 | 9.99% | 13G (passive) | Jul 14, 2026 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (11.30%), Baker Bros. Advisors (GP) LLC (11.30%) and 1 more | 4,257,735 | 11.30% | 13G (passive) amendment | Mar 31, 2025 |
| Brian F. Sullivan | 4,013,203 | 9.10% | 13G (passive) amendment | Sep 30, 2025 |
| Soleus Capital Master Fund, L.P. Joint filing with Soleus Capital, LLC (9.90%), Soleus Capital Group, LLC (9.90%) and 3 more | 3,872,184 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Nea 18 Vge Gp, LLC Joint filing with Growth Equity Opportunities 18 VGE, LLC (8.10%), NEA 18 Venture Growth Equity, L.P. (8.10%) and 9 more | 3,535,561 | 8.10% | 13D (active) amendment | Aug 14, 2025 |
| Bank Of America Corp /De/ | 3,170,198 | 6.50% | 13G (passive) | Jun 30, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (6.80%), Perceptive Life Sciences Master Fund, Ltd. (6.80%) | 3,160,200 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (6.72%) | 3,111,111 | 6.72% | 13G (passive) | Dec 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong (6.30%) | 3,039,621 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Growth Equity Opportunities 18 VGE, LLC Joint filing with NEA 18 Venture Growth Equity, L.P. (6.30%), NEA Partners 18 VGE, L.P. (6.30%) and 9 more | 2,910,561 | 6.30% | 13D (active) amendment | Jan 14, 2026 |
| BlackRock, Inc. | 2,179,064 | 5.90% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CELC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 7,915,792 | 16.18% | $828.15M | – | 4.15% |
| Avoro Capital Advisors LLC | 3,400,000 | 6.95% | $355.71M | +25,000 | 3.19% |
| Rtw Investments, LP | 3,304,903 | 6.75% | $345.76M | +265,282 | 2.95% |
| Perceptive Advisors LLC | 3,197,200 | 6.53% | $334.49M | +70,000 | 5.02% |
| BlackRock, Inc. | 3,018,785 | 6.17% | $315.83M | +307,253 | 0.00% |
| State Street Corp | 1,955,304 | 4.00% | $204.56M | +436,599 | 0.01% |
| Vanguard Capital Management LLC | 1,874,137 | 3.83% | $196.07M | +91,243 | 0.00% |
| NEA Management Company, LLC | 1,710,561 | 3.50% | $178.96M | −575,000 | 11.27% |
| Soleus Capital Management, L.P. | 1,704,318 | 3.48% | $178.31M | +419,940 | 6.14% |
| Bank Of America Corp /De/ | 1,471,307 | 3.01% | $153.93M | +756,978 | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 1,451,014 | 2.97% | $151.81M | −262,986 | 1.58% |
| Morgan Stanley | 1,334,545 | 2.73% | $139.62M | −11,170 | 0.01% |
| Tang Capital Management LLC | 1,314,594 | 2.69% | $137.53M | +264,594 | 6.25% |
| Toronto Dominion Bank | 1,258,758 | 2.57% | $131.69M | +376,000 | 0.15% |
| Geode Capital Management, LLC | 1,111,662 | 2.27% | $116.33M | +220,592 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,025,837 | 2.10% | $107.32M | −253,979 | 0.01% |
| Wellington Management Group Llp | 906,595 | 1.85% | $94.85M | +477,643 | 0.02% |
| Goldman Sachs Group Inc | 870,449 | 1.78% | $91.07M | +105,474 | 0.01% |
| Point72 Asset Management, L.P. | 650,916 | 1.33% | $68.10M | +370,592 | 0.08% |
| Hood River Capital Management LLC | 628,411 | 1.28% | $65.74M | New | 0.48% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 274 | 57M | 100.0% | 61 / 108 | 79 / 60 | 12M | 4M |
| Q1 2026 | 276 | 49M | 100.0% | 75 / 96 | 79 / 30 | 9M | 5M |
| Q4 2025 | 237 | 48M | 98.3% | 86 / 81 | 57 / 22 | 15M | 6M |
| Q3 2025 | 176 | 39M | 80.0% | 95 / 44 | 33 / 14 | 17M | 10M |
| Q2 2025 | 95 | 32M | 64.8% | 16 / 37 | 27 / 15 | 4M | 3M |
| Q1 2025 | 94 | 31M | 63.1% | 14 / 34 | 27 / 22 | 3M | 2M |
| Q4 2024 | 103 | 30M | 62.2% | 19 / 38 | 30 / 21 | 5M | 4M |
| Q3 2024 | 105 | 30M | 61.4% | 21 / 45 | 17 / 8 | 6M | 3M |
| Q2 2024 | 93 | 29M | 60.1% | 23 / 37 | 21 / 9 | 9M | 7M |
| Q1 2024 | 79 | 27M | 54.9% | 24 / 24 | 18 / 4 | 11M | 2M |
| Q4 2023 | 59 | 18M | 37.1% | 6 / 25 | 14 / 3 | 5M | 2M |
| Q3 2023 | 57 | 15M | 31.4% | 5 / 19 | 15 / 4 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
249 funds held CELC in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CELC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,394,056 | 2.85% | $145.85M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,128,339 | 2.31% | $118.05M | 1.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 987,675 | 2.02% | $103.33M | 0.12% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 436,212 | 0.89% | $45.64M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 420,597 | 0.86% | $36.33M | 0.11% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 375,600 | 0.77% | $49.91M | 0.95% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 355,217 | 0.73% | $37.16M | 0.24% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 350,000 | 0.72% | $36.62M | 0.59% | Jun 30, 2026 |
| Small Cap Growth Fund | 339,390 | 0.69% | $29.32M | 0.53% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 289,540 | 0.59% | $30.29M | 0.31% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 286,166 | 0.58% | $29.94M | 1.18% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 270,240 | 0.55% | $28.27M | 0.19% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 222,657 | 0.46% | $23.29M | 0.35% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 195,580 | 0.40% | $20.46M | 1.14% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 185,483 | 0.38% | $24.65M | 0.06% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian F. Sullivan | Chief Executive Officer, Director | 3,200,983 | 6.54% | Aug 18, 2026 |
| Lance G. Laing | Chief Science Officer, Director | 1,271,000 | 2.60% | Aug 18, 2026 |
| Vicky Hahne | Chief Financial Officer | 37,808 | 0.08% | Aug 18, 2026 |
| Leo Furcht | Director | 12,780 | 0.03% | Oct 9, 2026 |
| David W. Gryska | Director | 893 | 0.00% | Oct 5, 2026 |
| Polly A. Murphy | Director | 6,530 | 0.01% | Jun 12, 2026 |
| Richard E. Buller | Director | 9,319 | 0.02% | Jun 12, 2026 |
| Charles R. Romp | Director | 1,745 | 0.00% | Jun 9, 2026 |
| Richard Nigon | Director | 100,865 | 0.21% | Jun 9, 2026 |
| David Dalvey | Director | 66,530 | 0.14% | Jun 9, 2026 |
| Bros. Advisors (GP) LLC Baker | – | 703,920 | 1.44% | Jul 16, 2026 |
| Felix Baker | – | 7,055,748 | 14.42% | Jul 16, 2026 |
| Julian Baker | – | 442,940 | 0.91% | Jul 16, 2026 |
| Bros. Advisors Lp Baker | – | – | – | Jul 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Leo Furcht Director | Oct 7, 2026 | Option exercise | +250 | $7.60 | $1.90K | 12,780 |
| David W. Gryska Director | Oct 1, 2026 | Award | +893 | – | – | 893 |
| Brian F. Sullivan Chief Executive Officer, Director | Aug 14, 2026 | Award | +80,000 | – | – | 1,450,199 |
| Vicky Hahne Chief Financial Officer | Aug 14, 2026 | Award | +16,000 | – | – | 37,808 |
| Lance G. Laing Chief Science Officer, Director | Aug 14, 2026 | Award | +20,000 | – | – | 1,271,000 |
| Julian Baker – | Jul 14, 2026 | Sale | −261,368 | $102.50 | $26.79M | 442,940 |
| Julian Baker – | Jul 14, 2026 | Sale | −2,838,632 | $102.50 | $290.96M | 4,372,852 |
| Leo Furcht Director | Jun 5, 2026 | Award | +1,530 | – | – | 12,530 |
| David Dalvey Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,530 |
| Polly A. Murphy Director | Jun 5, 2026 | Award | +1,530 | – | – | 6,530 |
| Charles R. Romp Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,745 |
| Richard E. Buller Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,530 |
| Richard Nigon Director | Jun 5, 2026 | Award | +1,530 | – | – | 80,565 |
| Lance G. Laing Chief Science Officer, Director | Jun 2, 2026 | Option exercise | +1,000 | $9.89 | $9.89K | 1,251,000 |
| Richard E. Buller Director | May 19, 2026 | Gift | +1,029 | – | – | 7,789 |
| Richard E. Buller Director | May 19, 2026 | Gift | −1,029 | – | – | 0 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −365 | $143.24 | $52.28K | 6,760 |
| Richard E. Buller Director | May 4, 2026 | Option exercise | +9,000 | $5.10 | $45.90K | 15,760 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −1,289 | $137.00 | $176.59K | 14,471 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −550 | $139.00 | $76.45K | 13,921 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −1,670 | $139.58 | $233.10K | 12,251 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −2,301 | $141.03 | $324.51K | 9,950 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −2,825 | $142.04 | $401.26K | 7,125 |
| David Dalvey Director | May 4, 2026 | Sale(10b5-1 plan) | −25,000 | $140.68 | $3.52M | 65,000 |
| Richard Nigon Director | Apr 9, 2026 | Gift | −10,000 | – | – | 79,035 |
| Richard E. Buller Director | Mar 31, 2026 | Sale(10b5-1 plan) | −675 | $110.83 | $74.81K | 6,760 |
| Richard E. Buller Director | Mar 31, 2026 | Option exercise | +3,000 | $5.10 | $15.30K | 9,760 |
| Richard E. Buller Director | Mar 31, 2026 | Sale(10b5-1 plan) | −2,325 | $110.11 | $256.01K | 7,435 |
| Charles R. Romp Director | Feb 11, 2026 | Award | +215 | – | – | 215 |
| David Dalvey Director | Jan 27, 2026 | Sale(10b5-1 plan) | −20,000 | $120.03 | $2.40M | 90,000 |
| Richard Nigon Director | Dec 15, 2025 | Gift | −19,975 | – | – | 89,035 |
| Richard E. Buller Director | Dec 5, 2025 | Sale | −1,510 | $106.04 | $160.12K | 6,760 |
| Richard E. Buller Director | Dec 5, 2025 | Option exercise | +3,000 | $5.50 | $16.50K | 9,760 |
| Richard E. Buller Director | Dec 5, 2025 | Sale | −1,490 | $105.34 | $156.96K | 8,270 |
| Leo Furcht Director | Dec 4, 2025 | Option exercise | +250 | $7.60 | $1.90K | 11,000 |
| Richard E. Buller Director | Dec 2, 2025 | Gift | −500 | – | – | 6,760 |
| Richard E. Buller Director | Dec 1, 2025 | Option exercise | +1,100 | $14.83 | $16.31K | 8,360 |
| Richard E. Buller Director | Dec 1, 2025 | Sale | −1,100 | $98.13 | $107.94K | 7,260 |
| David Dalvey Director | Nov 21, 2025 | Sale(10b5-1 plan) | −15,000 | $100.00 | $1.50M | 110,000 |
| Richard E. Buller Director | Nov 20, 2025 | Sale | −3,900 | $96.73 | $377.25K | 7,260 |
| Richard E. Buller Director | Nov 20, 2025 | Option exercise | +3,900 | $14.83 | $57.84K | 11,160 |
| Richard E. Buller Director | Nov 19, 2025 | Gift | −500 | – | – | 7,260 |
| Richard Nigon Director | Sep 11, 2025 | Option exercise | +3,245 | $7.56 | $24.53K | 109,010 |
| Richard Nigon Director | Sep 11, 2025 | Option exercise | +4,672 | $7.56 | $35.32K | 105,765 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +13,976 | $56.22 | $785.73K | 703,920 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +151,524 | $56.22 | $8.52M | 7,207,272 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +388 | $58.02 | $22.51K | 704,308 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +4,212 | $58.02 | $244.38K | 7,211,484 |
| Brian F. Sullivan Chief Executive Officer, Director | Sep 2, 2025 | Option exercise | +104,340 | $8.05 | $839.94K | 1,370,199 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −4,141 | $46.05 | $190.69K | 125,000 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −16,438 | $45.29 | $744.48K | 129,141 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −22,377 | $44.36 | $992.64K | 145,579 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −57,044 | $43.30 | $2.47M | 167,956 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −2,025 | $46.05 | $93.25K | 0 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −4,163 | $45.24 | $188.33K | 2,025 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −3,137 | $44.36 | $139.16K | 6,188 |
| Richard E. Buller Director | May 27, 2025 | Gift | −1,079 | – | – | 1,029 |
| Richard E. Buller Director | May 27, 2025 | Gift | +1,079 | – | – | 7,760 |
| Richard E. Buller Director | May 19, 2025 | Award | +1,029 | – | – | 2,108 |
| Brian F. Sullivan Chief Executive Officer, Director | Apr 14, 2025 | Gift | +8,155 | – | – | 1,265,859 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
28.66%
10M shares short
Days to cover
5.8
At 2M shares a day
Change since last report
+0.5%
From 10M shares
Short volume, 20 days
59.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Celcuity's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,865 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| 667, L.P. Former Affiliate | Jul 14, 2026 | 261,368 | $26.79M | Jul 14, 2026 | Purchases of shares of common stock in the open market See Remark 2 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Jul 14, 2026 | 2,838,632 | $290.96M | Jul 14, 2026 | Purchases of shares of common stock in the open market See Remark 2 |
| David Dalvey Director | May 4, 2026 | 25,000 | $3.52M | May 4, 2026 | INVESTMENT |
| Richard E. Buller Director | May 4, 2026 | 6,000 | $842.79K | May 4, 2026 | Option Exercise |
| Richard E. Buller Director | Mar 31, 2026 | 6,000 | $661.61K | Mar 31, 2026 | Option Exercise |
| David Dalvey Director | Jan 27, 2026 | 20,000 | $2.40M | Jan 27, 2026 | INVESTMENT |
| Richard E. Buller Director | Dec 5, 2025 | 3,000 | $317.04K | Dec 5, 2025 | Option Exercise |
| Richard E. Buller Director | Dec 1, 2025 | 1,100 | $107.94K | Dec 1, 2025 | Option Exercise |
| David Dalvey Director | Nov 21, 2025 | 15,000 | $1.50M | Nov 21, 2025 | INVESTMENT |
| Richard E. Buller Director | Nov 20, 2025 | 3,900 | $377.26K | Nov 20, 2025 | Option Exercise |
| David Dalvey Director | Jul 28, 2025 | 9,325 | $420.77K | Jul 28, 2025 | STOCK GRANT |
| Brightstone Venture Capital Fund LP Director | Jul 28, 2025 | 100,000 | $4.40M | Jul 28, 2025 | INVESTMENT |
| Richard E. Buller Director | Aug 23, 2024 | 700 | $11.87K | Aug 23, 2024 | RSU |
| Richard E. Buller Director | Apr 24, 2024 | 700 | $11.95K | Apr 24, 2024 | RSU |
| Richard E. Buller Director | Dec 20, 2023 | 700 | $10.06K | Dec 20, 2023 | RSU |
See a number that looks wrong?